Drug Half-Life
Drug Half-Life (
This half-life is distinct from the observed half-life in pharmacokinetic data, which may result from a mix of non-specific and target mediated clearance mechanisms. The units for half-life are days and the longer the half-life the slower the degradation of the drug.
Drug Half-Life in Assess
Antibody or antibody-like biotherapeutics generally have predictable linear pharmacokinetic (PK) properties. (Deng et al 2011, Dong et al. 2011, Betts et al. 2018) In the absence of direct measurements, typical values from clinical antibodies can be used. The half-life can also be measured in preclinical species and allometrically scaled to predict human PK. (Betts et al. 2018)
Typical Values for Antibodies
Species | References | |
---|---|---|
Mouse | 6.3 | Deng et al. 2011; Avery et al. 2016 |
Rat | 3.6 | Deng et al. 2011 |
Cyno | 7 | Betts et al. 2018; Singh et al. 2015; Deng et al. 2011 |
Human | 15 | Dirks and Meibohm 2010; Betts et al. 2018; Davada et. al.; Singh et al. 2015 |